BASELINE CHARACTERISTICS OF PATIENTS WITH INFLAMMATORY RHEUMATIC MUSCULOSKELETAL DISORDERS: DATA FROM A PROSPECTIVE OBSERVATIONAL COHORT FROM THE GERMAN REGISTRY LORE

Background: Disease and treatment pattern of patients (pts.) differ between clinical trials and observational cohorts. We initiated a large regional, prospective observational cohort of pts. with inflammatory rheumatic musculoskeletal diseases (iRMD) in order to set up a database to facilitate several investigations on epidemiology, diagnosis, and prognosis in the field of rheumatology. Objectives: The purpose of this study was to describe patients and disease characteristics in pts. with iRMD and to analyse prevalence and type of various comorbidities. Methods: Adult pts with a clinical diagnosis of iRMD were included in the LORE cohort, an ongoing prospective longitudinal observational cohort with follow-up visits according to a fixed protocol. The only inclusion criteria was a documented clinical diagnosis of iRMD according to their rheumatologist, e.g. rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (axSpA)), connective tissue diseases, vasculitis or other iRMDs (e.g. Behcet disease). We collected the following variables: sociodemographic data, clinical data, patient-reported outcome, and treatment. Descriptive analysis was performed and factors that may be predictive of patient global assessment were investigated using uni- and multivariable regression analyses. Results: A total of 3551 pts. (female 61.4%, mean age: 55.4 (15.6) years, 935 ≥65 years of age (26.3%)) were recruited. The most common diagnoses were RA (1618 (45.6%), axSpA (672 (18.9%) and PsA (491 (13.8%), followed by connective tissue diseases (351 (9.9%) and vasculitis (199 (5.6%). One third of pts had a symptom duration ≥10 years, moderate to severe depressive symptoms, moderate disease activity and impairments in health-related quality of life (Table 1). Patient global were lowest in vasculitis (34.8 (24.3) and highest in RA (43.3 (24.5)). Prednisolone dosage was highest in pts with vasculitis (8.3 (14.1)) and lowest in axSpA pts (5.1 (4.4)). Most pts with RA used csDMARDs (1119 (70.1%) compared to pts with axSpA (103 (15.9%). Proportion of pts. with bDMARDs ranged between axSpA (380 (56.5%) and myositis (2 (7.4%), whereas tsDMARDs use were highest in Behçet’s disease (3 (13.6%) and RA (101 (6.2%)). 2998 (84.4%)had at least one comorbidity. The prevalence of comorbidities were highest in the PMR population (79 (98,8%) and lowest in the axSpA group (493 (73,4%). Among all comorbidities, cardiovascular (1512 (42.6%) and musculoskeletal (1900 (53.5%) comorbidities were the most prevalent one. Results from multivariable regression analysis showed that higher CRP levels, longer symptom duration and higher number of comorbidities were associated with higher values of patient global, while male sex and use of bDMARDs were associated with lower values of patient global (Table 2). Conclusion: This large regional observational cohort showed differences in treatment pattern between various types of iRMDs. Our findings illustrate the potential impact of comorbidities on patients well-being and indicate that a more holistic management approach is needed. This large cohort should facilitate the conduct of researches in different areas in order to improve our knowledge on impact of disease of pts with iRMD. REFERENCES: NIL. Acknowledgements: NIL. Disclosure of Interests: Uta Kiltz AbbVie, Amgen, Eli Lilly, Fresenius, Hexal, Janssen, Novartis, UCB, AbbVie, Amgen, Eli Lilly, Fresenius, Hexal, Janssen, Novartis, UCB, AbbVie, Amgen, Fresenius, GSK, Hexal, Janssen, Novartis, UCB, Isaac Agyenim Luedemann: None declared, Imke Redeker: None declared, Katharina de Jong: None declared, Styliani Tsiami: None declared, Fouad Alshakaki: None declared, Ioana Andreica Abbvie, Amgen, BMS, Chugai, Janssen, Eli Lilly, MSD, Novartis, Pfizer, Sobi, Takkeda and UCB., Abbvie, Amgen, BMS, Chugai, Janssen, Eli Lilly, MSD, Novartis, Pfizer, Sobi, Takkeda and UCB., Abbvie, Amgen, BMS, Chugai, Janssen, Eli Lilly, MSD, Novartis, Pfizer, Sobi, Takkeda and UCB., Barbara Guminski: None declared, Ute Haeusler AbbVie, Amgen, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers-Squibb, Glaxo Smith Kline, Janssen, Lilly, Novartis, Onitsuka, Pfizer, UCB, Vifor, AbbVie, Amgen, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers-Squibb, Glaxo Smith Kline, Janssen, Lilly, Novartis, Onitsuka, Pfizer, UCB, Vifor, Dimitra Karagkiozidou: None declared, Hilal Kavruk: None declared, David Kiefer Abbvie, BMS, Roche, Chugai, Novartis, UCB, Sanofi, MSD, Merck, GSK, Janssen, Boehringer Ingelheim, Galapagos, Abbvie, BMS, Roche, Chugai, Novartis, UCB, Sanofi, MSD, Merck, GSK, Janssen, Boehringer Ingelheim, Galapagos, Abbvie und Novartis, Rafael Lochowski: None declared, Alina-Mihaela Patru: None declared, Philipp Sewerin AXIOM Health, AMGEN, AbbVie, Biogen, Bristol-Myers Squibb, Celgene, Chugai Pharma Marketing Ltd./ Chugai Europe, Deutscher Psoriasis-Bund, Gilead Sciences, Hexal Pharma, Janssen-Cilag, Johnson & Johnson, Lilly/ Lilly Europe/ Lilly Global, medi-login, Mediri GmbH, Novartis Pharma, Onkowissen GmbH, Pfizer, Roche Pharma, Rheumazentrum Rhein-Ruhr, Sanofi-Genzyme, Spirit Medical Communication, Swedish Orphan Biovitrum, UCB Pharma, AXIOM Health, AMGEN, AbbVie, Biogen, Bristol-Myers Squibb, Celgene, Chugai Pharma Marketing Ltd./ Chugai Europe, Deutscher Psoriasis-Bund, Gilead Sciences, Hexal Pharma, Janssen-Cilag, Johnson & Johnson, Lilly/ Lilly Europe/ Lilly Global, medi-login, Mediri GmbH, Novartis Pharma, Onkowissen GmbH, Pfizer, Roche Pharma, Rheumazentrum Rhein-Ruhr, Sanofi-Genzyme, Spirit Medical Communication, Swedish Orphan Biovitrum, UCB Pharma, AXIOM Health, AMGEN, AbbVie, Biogen, Bristol-Myers Squibb, Celgene, Chugai Pharma Marketing Ltd./ Chugai Europe, Deutscher Psoriasis-Bund, Gilead Sciences, Hexal Pharma, Janssen-Cilag, Johnson & Johnson, Lilly/ Lilly Europe/ Lilly Global, medi-login, Mediri GmbH, Novartis Pharma, Onkowissen GmbH, Pfizer, Roche Pharma, Rheumazentrum Rhein-Ruhr, Sanofi-Genzyme, Spirit Medical Communication, Swedish Orphan Biovitrum, UCB Pharma, Diana Vossen: Abbvie Deutschland GmbH & Co. KG, Amgen, Boehringer Ingelheim Pharma GmbH & Co. KG, Bristol-Myer Squibb, Celgene GmbH, Chugai Pharma GmbH,Gilead Sciences Inc., GlaxoSmithKline plc, Lilly Deutschland GmbH, Medac GmbH, Novartis Pharma GmbH, Pfizer Deutschland GmbH, UCB Pharma GmbH. ,: Abbvie Deutschland GmbH & Co. KG, Amgen, Boehringer Ingelheim Pharma GmbH & Co. KG, Bristol-Myer Squibb, Celgene GmbH, Chugai Pharma GmbH,Gilead Sciences Inc., GlaxoSmithKline plc, Lilly Deutschland GmbH, Medac GmbH, Novartis Pharma GmbH, Pfizer Deutschland GmbH, UCB Pharma GmbH. ,: Abbvie Deutschland GmbH & Co. KG, Amgen, Boehringer Ingelheim Pharma GmbH & Co. KG, Bristol-Myer Squibb, Celgene GmbH, Chugai Pharma GmbH,Gilead Sciences Inc., GlaxoSmithKline plc, Lilly Deutschland GmbH, Medac GmbH, Novartis Pharma GmbH, Pfizer Deutschland GmbH, UCB Pharma GmbH. , Sabina Waldecker-Gall: None declared, Xenofon Baraliakos AbbVie, Amgen, Chugai, Galapagos, Lilly, MSD, Novartis, Pfizer, UCB and Sandoz., AbbVie, Amgen, Chugai, Galapagos, Lilly, MSD, Novartis, Pfizer, UCB and Sandoz., AbbVie, Amgen, Chugai, Galapagos, Lilly, MSD, Novartis, Pfizer, UCB and Sandoz. DOI: 10.1136/annrheumdis-2024-eular.572 Keywords: Health services research, Disease-modifying Drugs (DMARDs), Outcome measures, Observational studies/ registry, Comorbidities Citation: , volume 83, supplement 1, year 2024, page 2110Session: Across diseases (Publication Only)

Health services research, Disease-modifying Drugs (DMARDs), Outcome measures, Observational studies/ registry, Comorbidities